Dicot has identified several new patent opportunities
Press release: Uppsala, February 21, 2022. Dicot announces that the company is strengthening its IP assets by identification and documentation of ten new patent opportunities as a result of the company's work to maximize shareholder value.As a developing pharmaceutical company, Dicot follows a pronounced partnering strategy with a plan to out-license the company's drug candidate LIB-01 with data from clinical phase 2 studies. To maximize shareholder value from future out-licensing deals, the company works with a strong patent strategy to offer future licensees the longest possible market